U.S. Uterine Fibroids Treatment Devices Market To Reach $4.71 Billion By 2030

U.S. Uterine Fibroids Treatment Devices Market Growth & Trends

The U.S. uterine fibroids treatment devices market size is anticipated to reach USD 4.71 billion by 2030 and is anticipated to expand at a CAGR of 9.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The U.S. uterine fibroids treatment devices industry is experiencing significant growth due to the rising awareness of fibroid treatment options, advancements in minimally invasive procedures, and increasing demand for uterus-preserving alternatives to hysterectomy. In addition, the growing prevalence of uterine fibroids among women of reproductive age and the availability of innovative treatment devices are key factors driving market expansion.

Innovations in fibroid treatment devices continue to transform patient care. Recent FDA approvals and product launches have concreted the way for more effective and less invasive treatment options. In September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the release of its new SMART OS 2.4 software technology for the Sonata System. This innovative treatment combines the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, offering an incision-free, uterus-preserving, transcervical option for treating symptomatic uterine fibroids. Such advancements highlight the industry’s commitment to improving patient outcomes while reducing procedural risks.

The market is shifting toward non-surgical and uterus-sparing treatment approaches. Traditional surgical procedures, such as hysterectomy, are being replaced by less invasive methods that offer reduced recovery time, fewer complications, and improved quality of life for patients. Hysteroscopic myomectomy, laparoscopic myomectomy, and non-invasive ultrasound therapy are gaining traction among patients and healthcare providers.

With ongoing technological advancements, increased insurance coverage for minimally invasive procedures, and a growing focus on women’s reproductive health, the U.S. uterine fibroids treatment devices industry is poised for sustained growth.

 Request a free sample copy or view report summary: U.S. Uterine Fibroids Treatment Devices Market Report

 U.S. Uterine Fibroids Treatment Devices Market Report Segmentation

• Based on technology, the surgical technologies segment dominates the market with the largest revenue share owing to the increasing prevalence of uterine fibroids among women, necessitating effective surgical interventions.

• Based on mode of treatment, the invasive treatment segment dominates the market with the largest revenue share owing to the high adoption of hysterectomy and myomectomy procedures, which offer definitive fibroid removal. Advancements in laparoscopic and robotic-assisted surgeries, along with strong insurance coverage, further solidified its market dominance.

• In January 2025, Hologic, Inc. acquired Gynesonics, Inc., a privately held company specializing in minimally invasive solutions for uterine fibroid treatment, for approximately USD 350 million. Gynesonics is renowned for its Sonata System, an innovative technology that combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation to treat symptomatic uterine fibroids without incisions.

U.S. Uterine Fibroids Treatment Devices Market Segmentation

For this report, Grand View Research has segmented the U.S. uterine fibroids treatment devices market on the basis of technology, mode of treatment:

U.S. Uterine Fibroids Treatment Devices Technology Outlook (Revenue, USD Million; 2018 - 2030)

• Surgical Techniques

  • Hysterectomy

  • Myomectomy

• Laparoscopic Techniques

  • Laparoscopic Myomectomy

  • Myolysis

• Ablation Techniques

  • Microwave Ablation

  • Hydrothermal Ablation

  • Cryoablation

  • Ultrasound Ablation

    • High Intensity Focused Ultrasound (HIFU)

    • MRI-guided Focused Ultrasound (MRgFUS)

• Embolization Techniques

U.S. Uterine Fibroids Treatment Devices Mode of Treatment Outlook (Revenue, USD Million; 2018 - 2030)

• Invasive Treatment

• Minimally Invasive Treatment

• Non-invasive Treatment

List of Key Players in the U.S. Uterine Fibroids Treatment Devices Market

• Medtronic

• Stryker

• Boston Scientific Corporation

• Insightec.

• CooperSurgical Inc.

• Hologic, Inc.

• CONMED Corporation.

• Merit Medical Systems.

• Minerva Surgical, Inc.